My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

15.83 -0.06 (-0.38%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

S&P 500 Rises 100 Points; Nasdaq Up 3% ↗

October 04, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 04, 2022

Gainers

Via Benzinga

Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap ↗

October 04, 2022

The company scrapped its hereditary angioedema drug due to safety issues.

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Tuesday ↗

October 04, 2022

On Tuesday, 44 companies hit new 52-week lows.

Via Benzinga

Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today? ↗

October 04, 2022

KALV stock investors are having a hard day as KalVista Pharmaceuticals just hit the brakes on a crucial clinical study.

Via InvestorPlace

KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients ↗

October 04, 2022

Via Benzinga

KalVista Pharma: Q1 Earnings Insights ↗

September 08, 2022

KalVista Pharma (NASDAQ:KALV) reported its Q1 earnings results on Thursday, September 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗

October 04, 2022

Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.

Via Benzinga

Nasdaq Surges 350 Points; Crude Oil Rises Sharply ↗

October 04, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.

Via Benzinga

FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday ↗

October 04, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Open Higher As Dow Jumps 550 Points ↗

October 04, 2022

U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.

Via Benzinga

Why Kalvista Pharmaceuticals Shares Are Down Over 50% ↗

October 04, 2022

Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 04, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 04, 2022

Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!

Via InvestorPlace

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 23, 2022

Via Benzinga

KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off ↗

August 23, 2022

KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema...

Via Benzinga

Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried ↗

August 22, 2022

Shares hit their lowest point since November on the FDA's decision in HAE.

Via Investor's Business Daily

Recap: KalVista Pharmaceuticals Q4 Earnings ↗

July 07, 2022

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q4 earnings results on Thursday, July 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

KalVista Pharmaceuticals: Q3 Earnings Insights ↗

March 10, 2022

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

KalVista Pharmaceuticals: Q2 Earnings Insights ↗

December 09, 2021

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the...

Via Benzinga

Why KalVista Pharmaceuticals' Stock Is Trading Higher Today ↗

September 15, 2021

KalVista Pharmaceuticals (NASDAQ:KALV) shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of...

Via Benzinga

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial ↗

September 14, 2021

The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 12, 2021

Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life...

Via Benzinga

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗

July 11, 2021

Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...

Via Benzinga

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...

Via Talk Markets

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.